Background: Periampullary cancers are uncommon malignancies, often amenable to surgery. Several studies have suggested a role for adjuvant chemotherapy and chemoradiotherapy in improving survival of patients with periampullary cancers, with variable results. The aim of this meta-analysis was to determine the survival benefit of adjuvant therapy for periampullary cancers.
Introduction
Periampullary cancers are uncommon malignancies with an age-standardized incidence of 0⋅6 per 100 000 population in the UK 1 . Surgical resection is the treatment modality of choice, with ampullary cancer accounting for 10-20 per cent of pancreaticoduodenectomies performed for periampullary carcinoma 2 . Despite its relatively higher resectability rates compared with pancreatic adenocarcinoma, however, the 5-year survival rate has been estimated at only 20-50 per cent 3 -5 . Adjuvant therapy, including chemotherapy and chemoradiotherapy, has thus been proposed as a treatment modality to enhance long-term survival.
In 1987, the Gastrointestinal Tumor Study Group 6 suggested a potential survival benefit to the use of adjuvant therapy for pancreatic adenocarcinoma. Following the results of this and other similar studies, there has been a suggestion that adjuvant treatment be employed for all periampullary cancers. The latter, however, defined as malignancies arising in the ampulla of Vater, but extending into the distal common bile duct or adjacent duodenum, are a pathologically distinct group of malignancies. Although not classified as such, histologically these cancers can be of two types, intestinal and pancreatobiliary, depending on the type of epithelium from which they arise. Clinically, they often present earlier as a result of local obstruction that leads to jaundice and pain, and there is no strong evidence to indicate that these tumours would respond in the same way as pancreatic cancer 7 . Chemotherapy may be beneficial in the context of advanced or metastatic ampullary cancers, where studies have shown a median overall survival of 12⋅5 months with certain regimens 8 . However, for resectable cancers, the use of adjuvant therapy potentially exposes the patient to high levels of toxicity with little benefit.
As there is no clear consensus on the most efficacious chemotherapy regimen and limited evidence available, practical guidelines regarding adjuvant therapy have not been produced. There is thus a clear need to understand better the role of adjuvant therapy in periampullary cancer, and to define that role in regard to prognostic factors, in order to avoid excess morbidity. The aim of this meta-analysis of the various regimens tested in the literature was to determine the survival benefit, if any, of adjuvant chemotherapy for periampullary cancers.
Methods

Literature search strategy
A literature search of PubMed, Ovid MEDLINE, Embase and Google Scholar electronic databases was conducted for studies published from 1 January 2000 to 31 December 2015 on the use of adjuvant chemotherapy in the treatment of periampullary cancer in patients who had undergone surgery with curative intent. Search MeSH terms used included ampullary cancer, ampulla of Vater, peri-ampullary neoplasm, peri ampullary, adjuvant chemotherapy and chemoradiotherapy, in various combinations and with the names of specific surgical procedures. Research titles were then screened for suitability and full-text copies were retrieved. A study was considered suitable if it provided survival data for more than 3 years for both an adjuvant therapy group (either chemotherapy or chemoradiotherapy) and a surgery-alone group (control) in the treatment of periampullary cancer. Further potentially appropriate papers were highlighted by assessing the reference lists and citations of the articles being screened. The literature search was completed independently by two authors, and discrepancies were discussed until a consensus regarding relevance had been reached. The data were extracted directly from the published Kaplan-Meier curves, verified for each study by each author independently, and collated into an anonymized database for analysis.
All studies that investigated the use of any chemotherapybased adjuvant regimen for patients who had undergone any surgical procedure with curative intent for either ampullary or periampullary cancer (defined as malignancy located in the distal common bile duct, ampulla of Vater or adjacent duodenum) were included. Exclusion criteria were studies with no available English translation, no full-text version available, those in which no Kaplan-Meier analysis was available, and those involving palliative surgery or an adjuvant regimen involving radiotherapy alone. For studies that met the inclusion criteria, the year of publication, population demographics, the number of patients enrolled, overall survival and any adverse outcomes reported were extracted. Kaplan-Meier curves of survival were assessed and survival was calculated and verified by two authors independently.
Quality of the studies
The Jadad appraisal 9 and Cochrane risk-of-bias tool 10 were implemented individually and independently to assess the quality and risk of bias of the included studies. The scores from each assessment were combined to give a composite summary score. Prompting questions are used to allow the reviewer to assess whether there is a risk of bias with respect each of the domains. A total score above 3 denotes a level of rigour in each. Although these scores are used primarily in randomized trials, for consistency they were incorporated into the appraisal of the non-randomized studies.
Statistical analysis
Calculations were performed by one author and verified by another. The logarithm of the hazard ratio (HR) with its 95 per cent c.i. was used as the primary summary statistic. To estimate the pooled HR and its variance, the HR was extracted from each study directly or by additional calculation, depending on the method of data presentation: annual mortality rates, survival curves, number of deaths or percentage freedom from death 11 .
Meta-analysis of data was conducted using a randomeffects model. Publication bias was explored graphically with funnel plots to detect asymmetry and any outliers. Interstudy heterogeneity was assessed using the χ 2 statistic, and the I 2 value was employed to determine the degree of variation not attributable to chance alone. This was graded as low (I 2 value below 25 per cent), moderate (I 2 value 25-75 per cent) or high (I 2 value above 75 per cent). The significance level was set at P < 0⋅050.
A further subgroup analysis of the included RCTs was conducted for further appraisal of the validity of the conclusions drawn.
A meta-regression was performed for quantitative assessment of the impact of T and N status of the tumour, and the grade of differentiation on the overall effect. Three co-variables of interest were created: T category (continuous variable with the ratio of T3-4 versus T1-2 in Abstracts evaluated after exclusion of duplicates n = 704
Full-text studies assessed n = 14
Full-text studies retrieved n = 93 Significance was set at P < 0⋅050. This study was performed in line with journal recommendations, following the MOOSE guidelines 12 , using appropriate statistical software (Stata ® /SE12; Stata Corporation, College Station, Texas, USA).
Results
Fourteen full-text articles met the inclusion criteria and were appraised following the literature search 4,7,13 -24 ( Fig. 1) . A total of 1671 patients were enrolled in the studies, 904 of whom underwent surgery alone (control group) and 767 who had adjuvant chemotherapy. Six studies were RCTs, two were prospective cohort studies and the remaining six were retrospective. All studies were published between 2000 and 2015. Demographics for these studies are shown in Table 1 , and tumour demographics in Table S1 (supporting information). A classical Whipple procedure was the most commonly undertaken operation (754 patients), and a pylorus-preserving pancreaticoduodenectomy was completed in 423 patients. In five studies 4, 18, 20, 22, 23 , all or some of the study patients had an unspecified resection.
Quality of the studies
Results of the quality analysis are shown in Fig. 2 . Only five of the 14 studies had a Jadad or risk-of-bias score of 3 or more, denoting a low level of quality of the included studies and a high potential risk of bias (Tables S2 and S3 , supporting information). However, the median composite score of 3⋅5 (range 1-6) would suggest a level of skew caused by the few high-quality studies included in the evaluation.
Survival outcomes
The pooled 5-year overall survival rate across the 14 studies was 37⋅5 per cent for the control group, compared with 40⋅0 per cent in the adjuvant chemotherapy group (HR 1⋅08, 95 per cent c.i. 0⋅91 to 1⋅28; I 2 = 39⋅1 per cent, P = 0⋅067) (Fig. 3) . There was moderate heterogeneity amongst the included studies (Fig. 4) .
Analysis of RCTs
For the six RCTs 4, 15, 17, 19, 22, 23 there was no difference in 5-year overall survival between control and adjuvant therapy groups (HR 1⋅01, 95 per cent c.i. 0⋅80 to 1⋅26; I 2 = 45⋅5 per cent, P = 0⋅102) (Fig. S1 , supporting information). However, there was moderate heterogeneity amongst the studies (Fig. S2 , supporting information). Control group represents patients who had a surgery-alone treatment paradigm. *Single values in parentheses are numbers of patients. †Dosage values are median and range. ‡Survival rate in 54 node-positive patients with Kaplan-Meier data available; §3-year survival rate. R, retrospective; RT, radiotherapy; 5-FU, 5-fluorouracil; n.s., not stated; P, prospective; MMC, mitomycin C. ¶Log rank test.
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Meta-regression
In three studies 4, 13, 16 stage data for the patients were not stated explicitly. Of the remaining studies, 407 patients in the surgery-alone group had T1 or T2 disease, compared with 239 patients in the adjuvant group (P = 0⋅086). Some 270 patients in the surgery-alone group had T3 or T4 disease versus 329 patients in the adjuvant group (P = 0⋅309).
Reference
Zhou et al. 24 Takada et al. 23 Smeenk et al. 22 Sikora et al. 21 Schiergens et al. 20 Hazard ratio Hazard ratio Neoptolemos et al. 19 Neoptolemos et al. 4 Narang et al. 18 Morak et al. 17 Lazaryan et al. 16 Krishnan et al. 7 Klikenbijl et al. 15 Lee et al. 14 Bhatia et al. 13 Favours control 0·113 1 8·85 Favours adjuvant Overall (I 2 = 39·1%, P = 0·067) Meta-regression analysis elicited that only advanced T category (T3-4) was independently associated with significantly worse 5-year overall survival (regression coefficient −0⋅14, P = 0⋅040) ( Table S5 , supporting information). Owing to the lack of demographic data no further subgroup analysis could be completed.
Discussion
This systematic review has demonstrated that no associated survival benefit was conferred by the use of adjuvant therapy in patients with periampullary cancer (5-year overall survival rate 40⋅0 per cent versus 37⋅5 per cent in patients who had surgery alone; P = 0⋅067).
Periampullary cancers represent a group of malignancies distinct from those arising from other hepatobiliary structures. These cancers are pathologically adenocarcinomas, and an estimated 80 per cent are amenable to surgical resection 23, 25 . However, this treatment regimen is often augmented by the use of adjuvant chemotherapy and chemoradiotherapy, especially amongst those with advanced disease. The pooled overall survival rates demonstrated in this study are congruent with current estimates 22, 26 , which suggest a 5-year survival rate for periampullary cancers of 30-50 per cent.
In addition to not revealing an apparent survival benefit, a number of side-effects were reported from the use of adjuvant therapy. Although no treatment-associated mortality was recorded, 32⋅2 per cent of patients who had adjuvant therapy experienced WHO grade 3 or 4 toxic effects, indicating a high number of potentially life-threatening consequences 27 . The evaluation of overall survival in this study is, therefore, more appropriate than simply appraising locoregional control, as it acknowledges a holistic approach and the detriment to survival of treatment-related complications. Furthermore, this effect is likely to represent an underestimate as five of the studies did not report toxicity. These side-effects were most commonly systemic in nature, including haematological disturbances, nausea and diarrhoea, and are frequently associated with the use of 5-fluorouracil 28 , which was the principal agent employed in the majority of the chemotherapeutic regimens.
The use of any adjunctive (neoadjuvant or adjuvant) therapy in the treatment of any malignancy involves a cost-benefit balance. The benefit is typically evaluated in terms of survival, and in this case no survival benefit was gained through adjuvant therapy. The cost is most commonly considered in terms of the complications resulting from adjunctive therapy and consequent impact on quality of life. This study again showed that approximately one-third of patients experience serious complications from adjuvant therapy. Therefore, in terms of a cost-benefit assessment, adjuvant therapy provided no benefit but conferred significant cost to the patient.
The use of adjuvant chemotherapy has been established in the treatment of pancreatic cancer, for which numerous studies have shown a survival benefit 29, 30 . Periampullary cancers, however, present earlier owing to their tendency to obstruct the distal common bile duct, and thus often have not yet invaded local vascular, lymphatic or neural structures 7, 29 . For this reason, the outcomes of surgical resection are better than those associated with pancreatic cancer. Periampullary cancers thus represent a distinct group of malignancies, and the likelihood that adjuvant therapy will bestow a survival benefit is an assumption by proxy.
In 2008, Krishnan and colleagues 7 published the findings from a series of 96 patients, which suggested a survival benefit for the use of adjuvant chemoradiotherapy in ampullary cancers. They proposed a role for adjuvant therapy in advanced or 'high-risk' patients, defining the latter as those with stage T3 or T4 disease, but failed to demonstrate any survival benefit over an observation-based strategy 31 . In contrast to these findings, the present study has shown through meta-regression analyses that high T category (T3 or T4), unlike lymph node status or high tumour grade, was associated with a worse 5-year overall survival. However, owing to the limited numbers of patients in each group within the included studies, it was not possible to analyse further the potential survival benefit conferred by adjuvant chemotherapy in these advanced cases alone. For this reason, there may be a potential role for adjuvant therapy in patients with advanced disease (T3 or T4), where the risk-benefit ratio of chemotherapy may favour a treatment trial.
The ambiguity with respect the term 'high risk' has led several studies to improve patient selection for trials of adjuvant therapy 32 . Colussi and co-workers 33 proposed a composite score whereby age above than 75 years, WHO performance status of 2, poorly differentiated tumour and stage IIb or III reduced the 5-year disease-free survival rate by 75 per cent. Other factors such as preoperative carbohydrate antigen 19-9 level, perineural invasion and high UICC stage have also been associated with reduced survival, and patients with these factors may more appropriately be offered a trial of adjuvant chemotherapy than those without the factors 34, 35 . Furthermore, periampullary cancers can be broadly divided into two subtypes, intestinal and pancreatobiliary, with effects on which treatments are suitable for an individual patient. The prognosis of these two subtypes has been shown to differ, with pancreatobiliary cancers having significantly worse progression-free and overall survival 36 . This difference may be related to their contrasting response to various chemotherapeutic regimens, with the pancreatobiliary type showing greater response to gemcitabine-based therapies, and the intestinal type responding better to fluoropyrimidine treatments 20, 37 . This discrepancy may also explain the fact that, for metastatic disease, some studies advocate a 5-fluoruracil regimen, whereas others suggest the use of a gemcitabine-cisplatin combination 38, 39 . Thus, in order to appreciate the true survival benefit, if any, of adjuvant therapy, the optimal chemotherapeutic regimens to be used in these pathologically high-risk subgroups require elucidation.
A number of limitations to this review were highlighted by the study quality analysis. Periampullary tumours represent a heterogeneous group of cancers, and the inclusion criteria for the studies differed accordingly. The exact inclusion criteria are shown in Table 1 , but most studies defined periampullary cancers as those emanating from the ampulla of Vater or periampullary structures. Despite being a limitation of this study, this echoes the clinical scenario, whereby such periampullary cancers would be treated in a similar fashion. Furthermore, two studies 14, 20 incorporated in situ carcinoma, although this would lead to an overestimation of overall survival and of the effect of adjuvant therapy. In addition, the majority of the studies constituted retrospective evaluation of single-centre practice, thereby affecting the generalizability of the results. Subgroup assessment of the RCTs alone echoed the findings of the primary analysis, demonstrating no overall survival benefit. This enhances the reliability of the conclusions drawn. Despite this, few studies were designated with a risk-of-bias or Jadad score greater than 3, owing to lack of blinding. Although these scores are designed primarily for the assessment of RCTs, a low score indicates potential biases within the non-randomized trials included. Despite this, similar findings were found in the prospective studies and RCTs included. Furthermore, although there was no significant difference between the stages of patients in the control and adjuvant therapy groups, other prognostic factors, including resection margin and histological subtype of the periampullary cancer, were not often stated explicitly, precluding them from the analysis. There is thus a potential for the adjuvant group to have a worse prognosis irrespective of treatment given, skewing the results. Owing to the significant heterogeneity in the treatment regimens used in the studies, with variation in the number of chemotherapy cycles and use of radiotherapy, it was not possible to analyse the value of the various treatment regimens employed. Despite 5-fluorouracil being the most commonly used agent, a range of chemotherapeutics were used by studies, limiting the generalizability of the results. These differences in the chemotherapy regimen employed highlight the issue in the clinical setting, where there remains a lack of consensus as to which is the most efficacious. plus gemcitabine versus gemcitabine for biliary tract cancer.
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Editor's comments
While the European Study Group for Pancreatic Cancer (ESPAC) adjuvant trials showed a clear benefit for chemotherapy after resection of pancreatic cancer, this meta-analysis found no survival gain in patients with periampullary cancer. Periampullary tumours represent a heterogeneous group of cancers and differ from pancreatic cancers in terms of tumour stage at presentation, histology, biology and response to chemotherapy. Hence, extrapolating results from studies done in patients with pancreatic cancer to periampullary cancer is at least doubtful.
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